FLAG-IDA is given as induction chemotherapy to eliminate leukemia cells from the body and to decrease symptoms from AML, such as bleeding, bruising, and recurrent infections. It may be …

Nov 18, 2024 · In this context, fludarabine, AraC, G-CSF, and idarubicin (FLAG-Ida) has previously been reported to be effective salvage therapy for younger adults failing …

Nov 18, 2024 · first course of daunorubicin and AraC (DA; including 165 not in remission) were randomly assigned between up to two further courses of DA or in-tensified …

Nov 15, 2022 · FLAG-Ida Combined with Gemtuzumab Ozogamicin (GO) Improves Event Free Survival in Younger Patients with Newly Diagnosed Acute Myeloid Leukaemia (AML) and …

We evaluated the efficacy and toxicity profiles of the combination of fludarabine, high-dose cytosine arabinoside (AraC), idarubicin, and granulocyte colony-stimulating factor (G-CSF) in …

Nov 18, 2024 · In this study of older patients with AML considered fit and with evidence of residual disease after first induction, chemotherapy intensification improved survival. DAC …

Forty-three consecutive patients with de novo and untreated non M3 AML aged 60 or less entered the study. The mean age of patients was 50 (range 15-60). The induction regimen (FLAG-Ida) …

AraC is the most active agent in AML and demonstrates a steep dose-response curve. High dose araC (HiDAC) typically refers to doses ≥ 1000mg/m 2. Dose-escalation of araC to doses up to …

Nov 15, 2022 · Commonly used re-induction therapies are high dose cytarabine (HiDAC) and triple therapy consisting of fludarabine, cytarabine, idarubicin combined with granulocyte …

Mar 15, 2003 · We evaluated the efficacy and toxicity profiles of the combination of fludarabine, high-dose cytosine arabinoside (AraC), idarubicin, and granulocyte colony-stimulating factor …